NCT00681369
Completed
Not Applicable
Observational Usage Study of Faslodex in Patients Suffering From Initial Breast Cancer in France
ConditionsBreast Cancer
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Breast Cancer
- Sponsor
- AstraZeneca
- Enrollment
- 217
- Primary Endpoint
- Evaluate Faslodex therapeutic strategy and treatment duration
- Status
- Completed
- Last Updated
- 15 years ago
Overview
Brief Summary
the purpose of this study is to describe the way Faslodex is used in France, in patients suffering from initial breast cancer, that is to evaluate Faslodex treatment duration and to determine patients profile
Investigators
Eligibility Criteria
Inclusion Criteria
- •Patients suffering from initial breast cancer, treated with Faslodex, treatment which was stopped during 2007
Exclusion Criteria
- Not provided
Outcomes
Primary Outcomes
Evaluate Faslodex therapeutic strategy and treatment duration
Time Frame: At the end of the study
Describe the characteristics of patients treated with Faslodex
Time Frame: At the end of the study
Similar Trials
Terminated
Not Applicable
Faslodex Observations During Regular Use by Advanced Mammacarcinoma PatientsBreast CancerNCT00241462AstraZeneca150
Completed
Not Applicable
Faslodex Specific Clinical Experience InvestigationBreast CancerNCT01501266AstraZeneca660
Completed
Not Applicable
Retrospective Study Assessment Treatment Response Faslodex®( 500 mg)Malignant Neoplasm of Breast Stage IVNCT01509625Isabel Blancas272
Completed
Not Applicable
Faslodex International Observational Non-Interventional Study in Advanced Breast Cancer (BC)Breast CancerNCT00880711AstraZeneca57
Completed
Not Applicable
A Treatment With Fulvestrant and Exemestane in Postmenopausal Patients With Advanced Hormone Receptor-Positive (HR) + Breast CancerPostmenopauseBreast CancerNCT01171417AstraZeneca570